Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries C4 Therapeutics, Inc. - Common Stock (NQ: CCCC ) 5.320 -0.110 (-2.03%) Streaming Delayed Price Updated: 12:45 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 280,679 Open 5.400 Bid (Size) 5.310 (3) Ask (Size) 5.330 (4) Prev. Close 5.430 Today's Range 5.180 - 5.400 52wk Range 1.060 - 11.88 Shares Outstanding 48,797,226 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 30, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 September 13, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Performance YTD -18.40% -18.40% 1 Month -11.48% -11.48% 3 Month +16.92% +16.92% 6 Month -32.66% -32.66% 1 Year +220.48% +220.48% More News Read More C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen September 10, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Key Takeaways From C4 Therapeutics Analyst Ratings May 09, 2024 Via Benzinga Breaking Down C4 Therapeutics: 4 Analysts Share Their Views February 26, 2024 Via Benzinga Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session September 09, 2024 Via Benzinga Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket September 09, 2024 Via Benzinga C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 September 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors September 03, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Participate in Upcoming September Investor Conferences August 29, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation August 14, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 01, 2024 Via InvestorPlace C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 01, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 July 16, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day July 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors June 10, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights May 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 29, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum April 09, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 April 08, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 March 05, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins March 04, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights February 22, 2024 From C4 Therapeutics, Inc. Via GlobeNewswire Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session February 20, 2024 Via Benzinga Topics Stocks Exposures US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
